Dwyer Justin, Johnston Robert B, O'Callaghan Clare, Kallianis Voula, Ross Margaret L
Department of Psychosocial Cancer Care, St Vincent's Hospital (Melbourne), Melbourne, VIC, Australia.
School of Business, University College Dublin, Dublin, Ireland.
Front Psychiatry. 2025 Apr 30;16:1541528. doi: 10.3389/fpsyt.2025.1541528. eCollection 2025.
Music has been identified as a central feature of psychedelic-assisted psychotherapy (PAP) and has hitherto been understood to amplify the psychedelic experience in a predictable way that has been codified into music recommendations and playlists.
To re-evaluate the nature and role of music within the participant's world during psychedelic-assisted psychotherapy.
Phenomenological analysis of participants' descriptions of music during a randomised control trial of PAP at end of life involving two doses and a semi-structured interview following each dose.
Music undergoes a profound change during PAP that radically transforms it from everyday recorded music into a series of internally generated multisensory and deeply personal experiences that arrive fully formed and are instantly known by the participant. Some of these are constituted into actors that collaborate with the participant and the psychotherapist in their ongoing psychotherapy endeavours. This stands in stark contrast with the everyday properties of music described by those in the placebo group.
An alternate understanding of music in PAP is suggested that radically departs from the view that music is "administered" as part of PAP. There are profound implications for the practise of PAP and further research.
Australian New Zealand Clinician Trials Registry identifier, ACTRN12619001225101.
音乐已被确认为迷幻辅助心理治疗（PAP）的核心特征，迄今为止，人们认为音乐以一种可预测的方式增强迷幻体验，这种方式已被编纂成音乐推荐和播放列表。
重新评估音乐在迷幻辅助心理治疗中在参与者世界中的本质和作用。
在一项针对临终患者的PAP随机对照试验中，对参与者在服用两剂药物期间对音乐的描述进行现象学分析，并在每剂药物服用后进行半结构化访谈。
在PAP过程中，音乐经历了深刻的变化，从日常录制的音乐彻底转变为一系列内在产生的多感官且极具个人色彩的体验，这些体验完整呈现，参与者能立即感知。其中一些体验构成了与参与者和心理治疗师在持续心理治疗过程中合作的“角色”。这与安慰剂组参与者所描述的音乐日常属性形成鲜明对比。
提出了对PAP中音乐的另一种理解，这与认为音乐作为PAP一部分被“施用”的观点截然不同。这对PAP的实践和进一步研究具有深远意义。
澳大利亚和新西兰临床试验注册中心标识符，ACTRN12619001225101。
